Back to Research Page


Through the Interdisciplinary Research Program (IDRP), QBRI aims to encourage researchers to tackle common scientific challenges across two or more of QBRI’s research centers while working together and stimulating biomedical research across different disciplines.

Translational Oncology Research Center

Translational Oncology Research Center’s Innovative Activities

Translational Oncology Research Center aims to be the regional hub for cancer research with its state-of-the-art equipment and highly skilled staff members. The center benefits from the well-equipped and resourceful laboratories to execute inventive and innovative ideas in cancer research, resulting in a number of discoveries.

Translational Oncology Research Center investigators have submitted several patent applications related to

  • Targeting lactate dehydrogenase C to improve treatment response to common anti-cancer drugs.
  • Therapeutic potential of lactate dehydrogenase C for immunotherapy.
  • Identification and therapeutic potential of mRNA and lncRNA-based signatures in the resistance of triple negative breast cancer (TNBC) to neoadjuvant chemotherapy.
QBRI image

Diabetes Research Center (DRC)

Innovation Activities of the DRC

  • Creating and developing intellectual property (IP) and commercial development.
  • Developing blood and urine-based tests for predicting the progression of diabetic kidney disease.
  • Developing dietary supplements for improved immune health and methods for treating COVID-19.
  • Generating induced pluripotent stem cells (iPSCs) with GLUT2 mutations.
  • Generating induced pluripotent stem cells (iPSCs) with FOXA2 deletion.
  • Establishing new human iPSC lines to study diabetes due to mutations in the glucokinase gene.
QBRI image

Neurological Disorders Research Center (NDRC)

Innovation Activities at NDRC

The innovative research efforts led by the NDRC investigators have resulted in a number of inventions that are impacting patient care. examples include:

  • Patent applications for antibodies directed against alpha-synucein linked to Parkinson’s disease.
  • Agreements with biopharmaceuticals (AFFiRiS, Idorsia, Herantis, and Lundbeck) to use in-house technologies.
  • Registration of QABY Biotech as a trademark with QF.
  • Licensing agreements with Abcam and Euroimmun to distribute in-house developed reagents.
  • The first AI Arabic digital phenotyping for social communication (a diagnostic tool for Autism).
QBRI image